Healthcare >> CEO Interviews >> October 17, 2003
DONALD F. CORCORAN is President, Chief Executive Officer and Director of
MethylGene Inc., a Montreal-based, chemistry-focused biopharmaceutical
company formed in 1997. MethylGene's current goal is the discovery and
development of rationally designed small molecule drugs against enzyme
targets with an initial focus on cancer and infectious diseases. Mr.
Corcoran led the formation of MethylGene during his tenure as Vice
President, International Operations and Business Development at Hybridon
Inc. While at Hybridon, Mr. Corcoran established a number of corporate
alliances with multinational health care companies valued at over $275
million. Prior to joining Hybridon in 1992, Mr. Corcoran was Business
Planning Manager at Schering Plough Pharmaceuticals and while employed
at Eli Lilly and Company from 1982 to 1991, served in a variety of
financial, accounting, marketing, human resources and
acquisition/strategic planning positions. Mr. Corcoran serves on the
Board of Directors of Tranzyme, Inc., an emerging biotechnology company
in the US. He began his business career as an Administrator with Burke
Rehabilitation Hospital, New York, in 1978. Mr. Corcoran received a BA
in Economics and Biology from Union College in 1978 and an MBA from The
Johnson Graduate School of Management, Cornell University in 1982. Profile
Mr. Corcoran: We are 85 people today, of which 68 are in research and
development. We are a product-oriented company working
